Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma

Belantamab mafodotin (BLMF) is an interesting therapeutic alternative for multiple myeloma (MM) patients pretreated with immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies. Scientific evidence on BLMF provides immature data about progression-free survival and overall...

Descripción completa

Detalles Bibliográficos
Autores principales: Gil-Sierra, Manuel David, Briceño-Casado, Maria Del Pilar, Julia-Luna, Francisco Javier, Martinez-Moya, Maria Dolores
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Drug Watch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846917/
https://www.ncbi.nlm.nih.gov/pubmed/36537407
http://dx.doi.org/10.4103/ijp.ijp_563_21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846917/
https://www.ncbi.nlm.nih.gov/pubmed/36537407
http://dx.doi.org/10.4103/ijp.ijp_563_21

Ejemplares similares